Please login to the form below
Focus on multiple myeloma treatment: Witnessing a transformation
Consultant David Cooney of Blue Latitude Health will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.
I get very excited by science,
specifically pharmacology, and when I was studying drug development I used to
read case studies about the impact ground-breaking drugs had, and imagine what
it must have been like to be part of that success. I used to harass an old mentor
of mine who was involved in the Herceptin launch for stories about introducing
such an innovative treatment, hoping one day I’d get a chance to be part of such
a transformation in care.
I'm now part of a team at Blue Latitude Health working in multiple myeloma (MM), and with each publication that emerges, it’s clear that we are witnessing a transformation in the treatment of multiple myeloma. In this article, I will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.
If we reflect on what the treatment options were 10 years ago, two drugs stand out – melphalan and thalidomide. Melphalan, a distant cousin of the mustard gas used to kill World War I soldiers, and thalidomide, the infamous chiral drug which caused birth defects in the 1960s. These drugs have been shown to be efficacious options for patients with MM, but with a low therapeutic index. This meant significant cost in terms of toxicity, and marginal impact on the overall survival of patients.
![]()
I'm now part of a team at Blue Latitude Health working in multiple myeloma (MM), and with each publication that emerges, it’s clear that we are witnessing a transformation in the treatment of multiple myeloma. In this article, I will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.
The Therapeutic Index of multiple myeloma therapies
“It is easy to be overwhelmed by hype in cancer research, with promising new discoveries often portrayed as so-called game changers….but myeloma is a rare exception” [sic] was the opening of a recent editorial in the Lancet on multiple myeloma. To appreciate the context of this statement we need to consider what treatment options were like for myeloma patients in the past.If we reflect on what the treatment options were 10 years ago, two drugs stand out – melphalan and thalidomide. Melphalan, a distant cousin of the mustard gas used to kill World War I soldiers, and thalidomide, the infamous chiral drug which caused birth defects in the 1960s. These drugs have been shown to be efficacious options for patients with MM, but with a low therapeutic index. This meant significant cost in terms of toxicity, and marginal impact on the overall survival of patients.
Download the full article from Blue Latitude Health
Company Details
Blue Latitude Health
+44 203 328 1840
Address:
Blue Latitude Health
Crusader House
145-157 St John Street
London
EC1V 4QJ
United Kingdom
Latest content on this profile
- The dark side of direct-to-consumer genetic tests
- Direct-to-consumer testing is an affordable way to better understand your DNA, but is this a leap forward in innovation or another layer clouding an already complex market? From anxious patients to unnecessary surgeries, we reveal the barriers for healthcare professionals and patients, and how to solve these industry challenges.
Blue Latitude Health
- Genetic counsellors: the new healthcare influencers?
- Blue Latitude Health explores the relationship between physicians and genetic counsellors, and the impact this has on turning precision medicine into a reality for oncology patients.
Blue Latitude Health
- Mastering the precision medicine opportunity
- The rise of precision medicine will transform the pharma business model, challenging the way we commercialise therapies. BLH Senior Consultant and precision medicine expert David Cooney, reveals how you can plan for this change.
Blue Latitude Health
- Medopad: the up and coming unicorn transforming remote patient monitoring
- Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases.
Blue Latitude Health
- Bringing the NHS into the 21st century
- As the NHS celebrates its 70th birthday and a £20bn “birthday gift” from the UK government, we find out how one company is delivering what the National Health Service really needs – a financially sustainable method of healthcare management. Dr Kruti Patel Clinical Operations Manager at virtual healthcare provider Medefer tells us more.
Blue Latitude Health
- Successful brands tell stories
- Creating a strong brand story is the first step in developing a successful pharma brand. Here, Head of Insight Martine Leroy and Jocelyn Coutinho reveal the tools and techniques they use to create a narrative that makes an impact.
Blue Latitude Health
- About us
- Contact us
- How to advertise
- Site map
- All content copyright © PMGroup Worldwide Ltd 2018
